pomegranate glp-1 Health – GLP1 Match Pomegranate Nature’s GLP-1 (Ozempic), Scientists

As we look to 2026, the story becomes one of defining firsts: the debut of oral GLP-1s, the first loss of exclusivity for a GLP-1 receptor antagonist, and landmark coverage decisions such as obesity medications entering Medicare formularies for obesity as a standalone indication

When patients on medications for opioid, alcohol, or nicotine use disorder were excluded from the analysis, the association strengthened to a 44% lower risk during active GLP-1 use

For obesity treatment, only liraglutide 3.0 mg, semaglutide 2.4 mg, and tirzepatide 5, 10, and 15 mg are licenced in adults

doi: 10.1007/s00125-023-05906-7

We will name the trade-offs

(NASDAQ: NTRB, NTRBW) announced that CEO and Co-Founder Gareth Sheridan was featured on the latest episode of the Jack Neel Podcast